BioCryst Pharmaceuticals, Inc. (BCRX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

19/25

Growth 5 Margin 4 Expansion 4 Platform 2 Financial 4

latest quarter score

Earnings Reports

19
BioCryst (BCRX) Q2 2026: Operating Profit Hits $113M as Pipeline Shifts to External Innovation
August 05, 2026
20
BioCryst (BCRX) Q1 2026: Orladeyo Revenue Jumps 21% as Pipeline Execution Accelerates
May 06, 2026
21
BioCryst (BCRX) Q4 2025: Orladeyo Revenue Jumps 43% as HAE Franchise Deepens Portfolio
February 26, 2026
18
BioCryst (BCRX) Q3 2025: Orladeyo Drives 37% Growth as Rare Disease Pipeline Expands
November 03, 2025
20
BioCryst (BCRX) Q2 2025: Orladeyo Surges 45% as U.S. Prescriber Base Expands
August 04, 2025
19
BioCryst (BCRX) Q1 2025: Paid Patient Rate Surges 10 Points, Accelerating Profitability Timeline
July 06, 2025
BioCryst (BCRX) Q3 2024: Orladeyo Grows 36% as Paid Rate Rises to 74.8%, Pushing Toward Profitability
November 04, 2024
BioCryst (BCRX) Q2 2024: Orladeyo Nears 20% U.S. Market Share as Paid Patient Base Hits 82% in Commercial Segment
August 05, 2024
BioCryst (BCRX) Q1 2024: Orladeyo Revenue Jumps 30% as Pipeline Readies for Clinical Expansion
May 06, 2024
BioCryst (BCRX) Q4 2023: Orladeyo Patient Base Surges by 321, Underscoring Durable Growth Path
February 26, 2024
16
BioCryst (BCRX) Q3 2023: Orladeyo U.S. Patient Base Surpasses 1,000, Locking in Linear Growth Path
November 02, 2023
BioCryst (BCRX) Q2 2023: Orladeyo Paid Rate Falls to 30% as Patient Growth Drives $81M Revenue Step-Up
August 03, 2023
BioCryst (BCRX) Q1 2023: Orladeyo Patient Base Up 46%, Fueling $1B Peak Sales Ambition
May 03, 2023
BioCryst (BCRX) Q4 2022: Orladeyo Revenue Doubles, $320M Guidance Anchored by Expanding Prescriber Base
February 21, 2023

Browse all companies